Trikafta is a prescription medication used to treat cystic fibrosis (CF), a genetic disease that causes thick, sticky mucus to build up in the lungs, digestive tract, and other organs. It is FDA-approved for patients aged 2 and older who carry at least one copy of the most common CF-causing mutation, known as F508del, or another mutation shown to respond to the drug in lab testing. Roughly 90% of people with cystic fibrosis carry at least one F508del mutation, making Trikafta the most widely eligible CF treatment available.
How Trikafta Works
Cystic fibrosis is caused by defects in a protein called CFTR, which normally sits on the surface of cells and acts as a channel for chloride (a component of salt) and water to flow in and out. When CFTR is misshapen or missing from the cell surface, chloride can’t move properly, and the result is the thick, dehydrated mucus that defines the disease.
Trikafta is a combination of three active compounds that attack this problem from two angles. Two of them are “correctors” that help the defective CFTR protein fold into the right shape and travel to the cell surface, where it belongs. The third is a “potentiator” that holds the chloride channel open once the protein arrives, allowing chloride to flow through more normally. This two-step fix, getting the protein to the surface and then making it work, is what makes the triple combination so much more effective than earlier single or dual therapies.
Who Is Eligible
Trikafta is approved for anyone aged 2 years and older with at least one F508del mutation in the CFTR gene. It also covers a broader list of rarer mutations that have been shown to respond in laboratory testing. If a patient’s specific mutation isn’t already known, an FDA-cleared CF mutation test is used to confirm eligibility before starting treatment.
This broad genetic coverage was a major shift. Earlier CFTR modulators worked only for a narrow slice of CF patients. Trikafta’s approval dramatically expanded the number of people who could benefit from a therapy that targets the root cause of the disease rather than just managing symptoms.
Clinical Benefits
The clearest measure of Trikafta’s impact is lung function. In phase 3 clinical trials, patients saw an average improvement of 13.8 percentage points in lung function (measured by the volume of air they could forcefully exhale in one second) compared to placebo. A second head-to-head trial comparing Trikafta against an older dual-therapy modulator showed a 10-percentage-point advantage for Trikafta. For context, even a few percentage points of lung function can translate into noticeably easier breathing, better exercise tolerance, and fewer days feeling sick.
Trikafta also has a measurable effect on sweat chloride levels, which serve as a biomarker for how well CFTR is functioning throughout the body. In real-world data, patients who carry two copies of the F508del mutation saw their sweat chloride drop by 59%, from an average of 104 mmol/L down to 60 mmol/L. Those with one copy of the mutation experienced a 48% reduction. Lower sweat chloride signals that the underlying protein defect is being partially corrected at a cellular level, not just in the lungs.
Beyond these numbers, many patients and clinicians report improvements that are harder to quantify: fewer lung infections (called pulmonary exacerbations), reduced need for hospitalizations, weight gain, and better quality of life overall. For a disease that historically involved relentless decline, these changes have been described as paradigm-shifting.
How It Is Taken
Trikafta is taken as two separate doses each day, roughly 12 hours apart. The morning dose combines all three active ingredients, while the evening dose contains only the potentiator. Both doses need to be taken with fat-containing food, such as eggs, peanut butter, cheese, or whole milk, because the medication absorbs significantly better when fat is present in the gut.
One important dietary restriction: grapefruit and grapefruit juice should be avoided entirely while on Trikafta. Grapefruit interferes with the same liver enzymes that break down the drug, which can cause medication levels in the blood to rise unpredictably.
Drug Interactions to Know About
Trikafta is processed by a group of liver enzymes that also metabolize many common medications, particularly certain antifungals and antibiotics. Strong inhibitors of these enzymes, including antifungal drugs like ketoconazole and itraconazole, can increase the drug’s concentration in the blood by several fold. Moderate inhibitors like fluconazole and erythromycin have a smaller but still meaningful effect. When these medications are necessary, the Trikafta dosing schedule is adjusted to compensate, sometimes reduced to just a few days per week.
Because CF patients frequently take antibiotics and antifungals to manage lung infections, these interactions come up regularly in practice. Your CF care team will adjust your Trikafta schedule whenever a conflicting medication is added or removed.
Monitoring and Side Effects
The most important safety concern with Trikafta involves the liver. Liver enzyme levels are checked before starting the medication, then monthly for the first six months, every three months for the following year, and at least annually after that. Patients with a history of liver disease or elevated liver enzymes at baseline may need even more frequent monitoring. Most liver enzyme elevations are mild and reversible, but they need to be caught early.
For children starting Trikafta, baseline eye exams are recommended, along with follow-up checks, because cataracts (clouding of the lens) have been observed in pediatric patients taking CFTR modulators in preclinical and clinical settings.
The most commonly reported side effects in clinical trials were relatively mild: headache, upper respiratory symptoms, stomach pain, and rash. For most patients, these are manageable and tend to lessen over the first weeks of treatment. A subset of patients also notice temporary changes in mental health, including increased anxiety or mood shifts, which should be discussed with a care team if they persist.